Skip to main content
main-content
Top

Tip

Swipe om te navigeren naar een ander artikel

Gepubliceerd in: Quality of Life Research 6/2013

01-08-2013

Superselective α-adrenergic blockers versus transurethral resection of the prostate: a prospective comparison of health-related quality of life outcome after treating patients with benign prostatic hyperplasia

Auteurs: Negin Hadi, Alireza Aminsharifi, Ali Sadeghi, Ali Tourchi

Gepubliceerd in: Quality of Life Research | Uitgave 6/2013

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Purpose

We prospectively evaluated the impact of transurethral resection of the prostate (TURP) versus superselective α-adrenergic blocker treatment on health-related quality of life (HRQOL) in men with clinically diagnosed benign prostatic hyperplasia (BPH).

Patients and methods

A total of 219 patients with lower urinary tract symptoms (LUTS) caused by BPH were recruited in this study. Treatment modalities consisted of standard TURP (n = 104) and tamsulosin medical treatment (n = 115). HRQOL was assessed by SF-36-Item Health Survey 1.0. LUTS were estimated by The International Prostate Symptom Score. Patients’ outcome 4 weeks after treatment was compared to pre-treatment status and to that of the other group. Statistically significant changes in each HRQOL scale from baseline to follow-up period were investigated.

Results

Baseline characteristics were similar in both groups except for the duration of disease before treatment that was longer in TURP group. Both treatments resulted in statistically significant improvements from pre-treatment in all scales of QOL after 4 weeks, with no significant differences observed between the two groups. In medical treatment group, there was a significant association between higher educational level and better QOL in all 8 scales. Our outcomes revealed a significant decrease in the IPSS in both groups but this improvement was more evident in TURP group.

Conclusion

All scales concerning HRQOL were favorably improved 4 weeks after both surgical and medical treatment, and no significant differences were observed between these two treatment modalities for patients with symptomatic BPH. This information may aid patients when deciding which treatment option to take.
Literatuur
1.
go back to reference Chute, C. G., Panser, L. A., Girman, C. J., et al. (1993). The prevalence of prostatism: A population-based survey of urinary symptoms. Journal of Urology, 150, 85–89. PubMed Chute, C. G., Panser, L. A., Girman, C. J., et al. (1993). The prevalence of prostatism: A population-based survey of urinary symptoms. Journal of Urology, 150, 85–89. PubMed
2.
go back to reference Chow, R. D. (2001). Benign prostatic hyperplasia. Patient evaluation and relief of obstructive symptoms. Geriatrics, 56, 33–38. PubMed Chow, R. D. (2001). Benign prostatic hyperplasia. Patient evaluation and relief of obstructive symptoms. Geriatrics, 56, 33–38. PubMed
3.
go back to reference Eckhardt, M. D., van Venrooij, G. E., van Melick, H. H., & Boon, T. A. (2001). Prevalence and bothersomeness of lower urinary tract symptoms in benign prostatic hyperplasia and their impact on well-being. Journal of Urology, 166, 563–568. PubMedCrossRef Eckhardt, M. D., van Venrooij, G. E., van Melick, H. H., & Boon, T. A. (2001). Prevalence and bothersomeness of lower urinary tract symptoms in benign prostatic hyperplasia and their impact on well-being. Journal of Urology, 166, 563–568. PubMedCrossRef
4.
go back to reference Bruskewitz, R. C. (2003). Quality of life and sexual function in patients with benign prostatic hyperplasia. Rev Urol, 5, 72–80. PubMed Bruskewitz, R. C. (2003). Quality of life and sexual function in patients with benign prostatic hyperplasia. Rev Urol, 5, 72–80. PubMed
5.
go back to reference Kaplan, S. A. (2005). Benign prostatic hyperplasia: Patient perceptions and financial reality regarding the aging American prostate. Journal of Urology, 173, 1852. PubMedCrossRef Kaplan, S. A. (2005). Benign prostatic hyperplasia: Patient perceptions and financial reality regarding the aging American prostate. Journal of Urology, 173, 1852. PubMedCrossRef
6.
go back to reference Arai, Y., Aoki, Y., Okubo, K., et al. (2000). Impact of interventional therapy for benign prostatic hyperplasia on quality of life and sexual function: A prospective study. Journal of Urology, 164, 1206–1211. PubMedCrossRef Arai, Y., Aoki, Y., Okubo, K., et al. (2000). Impact of interventional therapy for benign prostatic hyperplasia on quality of life and sexual function: A prospective study. Journal of Urology, 164, 1206–1211. PubMedCrossRef
7.
go back to reference O’Leary, M. P., Roehrborn, C., Andriole, G., et al. (2003). Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor. BJU International, 92, 262–266. PubMedCrossRef O’Leary, M. P., Roehrborn, C., Andriole, G., et al. (2003). Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor. BJU International, 92, 262–266. PubMedCrossRef
8.
go back to reference Roehrborn, C. G., Van Kerrebroeck, P., & Nordling, J. (2003). Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: A pooled analysis of three double-blind, placebo-controlled studies. BJU International, 92, 257–261. PubMedCrossRef Roehrborn, C. G., Van Kerrebroeck, P., & Nordling, J. (2003). Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: A pooled analysis of three double-blind, placebo-controlled studies. BJU International, 92, 257–261. PubMedCrossRef
9.
go back to reference Narayan, P., Evans, C. P., & Moon, T. (2003). Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Journal of Urology, 170, 498–502. PubMedCrossRef Narayan, P., Evans, C. P., & Moon, T. (2003). Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Journal of Urology, 170, 498–502. PubMedCrossRef
10.
go back to reference Cambio, A. J., & Evans, C. P. (2007). Outcomes and quality of life issues in the pharmacological management of benign prostatic hyperplasia (BPH). Therapeutics and Clinical Risk Management, 3, 181–196. PubMedCrossRef Cambio, A. J., & Evans, C. P. (2007). Outcomes and quality of life issues in the pharmacological management of benign prostatic hyperplasia (BPH). Therapeutics and Clinical Risk Management, 3, 181–196. PubMedCrossRef
11.
go back to reference Suzuki, H., Yano, M., Awa, Y., et al. (2006). Clinical impact of tamsulosin on generic and symptom-specific quality of life for benign prostatic hyperplasia patients: Using international prostate symptom score and rand medical outcomes study 36-item health survey. International Journal of Urology, 13, 1202–1206. PubMedCrossRef Suzuki, H., Yano, M., Awa, Y., et al. (2006). Clinical impact of tamsulosin on generic and symptom-specific quality of life for benign prostatic hyperplasia patients: Using international prostate symptom score and rand medical outcomes study 36-item health survey. International Journal of Urology, 13, 1202–1206. PubMedCrossRef
12.
go back to reference Narayan, P., & Lepor, H. (2001). Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia. Urology, 57, 466–470. PubMedCrossRef Narayan, P., & Lepor, H. (2001). Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia. Urology, 57, 466–470. PubMedCrossRef
13.
go back to reference Boyd, S. D., & Narayan, P. (1994). Management of benign prostatic hyperplasia. Western Journal of Medicine, 160, 165–166. PubMed Boyd, S. D., & Narayan, P. (1994). Management of benign prostatic hyperplasia. Western Journal of Medicine, 160, 165–166. PubMed
14.
go back to reference Soderdahl, D. W., Knight, R. W., & Hansberry, K. L. (1996). Erectile dysfunction following transurethral resection of the prostate. Journal of Urology, 156, 1354–1356. PubMedCrossRef Soderdahl, D. W., Knight, R. W., & Hansberry, K. L. (1996). Erectile dysfunction following transurethral resection of the prostate. Journal of Urology, 156, 1354–1356. PubMedCrossRef
15.
go back to reference Deliveliotis, C., Liakouras, C., Delis, A., et al. (2004). Prostate operations: Long-term effects on sexual and urinary function and quality of life. Comparison with an age-matched control population. Urological Research, 32, 283–289. PubMedCrossRef Deliveliotis, C., Liakouras, C., Delis, A., et al. (2004). Prostate operations: Long-term effects on sexual and urinary function and quality of life. Comparison with an age-matched control population. Urological Research, 32, 283–289. PubMedCrossRef
16.
go back to reference Ware, J. E., Jr, & Gandek, B. (1998). Overview of the SF-36 health survey and the international quality of life assessment (IQOLA) project. Journal of Clinical Epidemiology, 51, 903–912. PubMedCrossRef Ware, J. E., Jr, & Gandek, B. (1998). Overview of the SF-36 health survey and the international quality of life assessment (IQOLA) project. Journal of Clinical Epidemiology, 51, 903–912. PubMedCrossRef
17.
go back to reference Montazeri, A., Goshtasebi, A., Vahdaninia, M., & Gandek, B. (2005). The short form health survey (SF-36): Translation and validation study of the Iranian version. Quality of Life Research, 14, 875–882. PubMedCrossRef Montazeri, A., Goshtasebi, A., Vahdaninia, M., & Gandek, B. (2005). The short form health survey (SF-36): Translation and validation study of the Iranian version. Quality of Life Research, 14, 875–882. PubMedCrossRef
18.
go back to reference Bosch, J. L., Hop, W. C., Kirkels, W. J., & Schroder, F. H. (1995). The international prostate symptom score in a community-based sample of men between 55 and 74 years of age: Prevalence and correlation of symptoms with age, prostate volume, flow rate and residual urine volume. British Journal of Urology, 75, 622–630. PubMedCrossRef Bosch, J. L., Hop, W. C., Kirkels, W. J., & Schroder, F. H. (1995). The international prostate symptom score in a community-based sample of men between 55 and 74 years of age: Prevalence and correlation of symptoms with age, prostate volume, flow rate and residual urine volume. British Journal of Urology, 75, 622–630. PubMedCrossRef
19.
go back to reference Salinas-Sanchez, A. S., Hernandez-Millan, I., Lorenzo-Romero, J. G., et al. (2001). Quality of life of patients on the waiting list for benign prostatic hyperplasia surgery. Quality of Life Research, 10, 543–553. PubMedCrossRef Salinas-Sanchez, A. S., Hernandez-Millan, I., Lorenzo-Romero, J. G., et al. (2001). Quality of life of patients on the waiting list for benign prostatic hyperplasia surgery. Quality of Life Research, 10, 543–553. PubMedCrossRef
20.
go back to reference O’Sullivan, M., Murphy, C., Deasy, C., et al. (2004). Effects of transurethral resection of prostate on the quality of life of patients with benign prostatic hyperplasia. Journal of the American College of Surgeons, 198, 394–403. PubMedCrossRef O’Sullivan, M., Murphy, C., Deasy, C., et al. (2004). Effects of transurethral resection of prostate on the quality of life of patients with benign prostatic hyperplasia. Journal of the American College of Surgeons, 198, 394–403. PubMedCrossRef
21.
go back to reference Donovan, J. L., Peters, T. J., Neal, D. E., et al. (2000). A randomized trial comparing transurethral resection of the prostate, laser therapy and conservative treatment of men with symptoms associated with benign prostatic enlargement: The CLasP study. Journal of Urology, 164, 65–70. PubMedCrossRef Donovan, J. L., Peters, T. J., Neal, D. E., et al. (2000). A randomized trial comparing transurethral resection of the prostate, laser therapy and conservative treatment of men with symptoms associated with benign prostatic enlargement: The CLasP study. Journal of Urology, 164, 65–70. PubMedCrossRef
22.
go back to reference Gacci, M., Bartoletti, R., Figlioli, S., et al. (2003). Urinary symptoms, quality of life and sexual function in patients with benign prostatic hypertrophy before and after prostatectomy: A prospective study. BJU International, 91, 196–200. PubMedCrossRef Gacci, M., Bartoletti, R., Figlioli, S., et al. (2003). Urinary symptoms, quality of life and sexual function in patients with benign prostatic hypertrophy before and after prostatectomy: A prospective study. BJU International, 91, 196–200. PubMedCrossRef
23.
go back to reference Tascı, A. I., Ilbey, Y. O., Tugcu, V., et al. (2011). Transurethral resection of the prostate with monopolar resectoscope: Single-surgeon experience and long-term results of after 3589 procedures. Urology, 78, 1151–1155. PubMedCrossRef Tascı, A. I., Ilbey, Y. O., Tugcu, V., et al. (2011). Transurethral resection of the prostate with monopolar resectoscope: Single-surgeon experience and long-term results of after 3589 procedures. Urology, 78, 1151–1155. PubMedCrossRef
Metagegevens
Titel
Superselective α-adrenergic blockers versus transurethral resection of the prostate: a prospective comparison of health-related quality of life outcome after treating patients with benign prostatic hyperplasia
Auteurs
Negin Hadi
Alireza Aminsharifi
Ali Sadeghi
Ali Tourchi
Publicatiedatum
01-08-2013
Uitgeverij
Springer Netherlands
Gepubliceerd in
Quality of Life Research / Uitgave 6/2013
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-012-0259-7